Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
- Registration Number
- NCT00551564
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis. Non-diabetics with IR are at risk, but can be difficult to diagnose.
A major problem with the use of IR as a predictor or marker of disease is the lack of a simple, robust test that can be used to quantify this parameter in a wide variety of clinical situations. The current 'gold standard' methods for measuring insulin sensitivity, such as the hyperinsulinemic-euglycemic (H-E) clamp, are complex, time consuming and costly. Alternative, simpler methods, such as the Homeostasis Model Assessment (HOMA-IR) score, may be less accurate and are not widely accepted.
- Detailed Description
A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- Male and/or females aged 18-65 years
- Females must either be of non-childbearing potential or childbearing potential (but not pregnant) and using appropriate methods of contraception.
- Healthy normal or overweight control subjects or healthy obese subjects or subjects with T2DM.
- Clinically significant past or current medical conditions
- Clinically significant abnormalities in vital signs or routine laboratory parameters
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Subjects in healthy normal and overweight control arm rosiglitazone maleate Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily. Subjects in healthy obese with T2DM arm rosiglitazone maleate Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
- Primary Outcome Measures
Name Time Method Insulin resistance baseline and after 8 weeks of Rosiglitazone treatment
- Secondary Outcome Measures
Name Time Method Insulin resistance baseline, after 2 weeks treatment, 2 weeks after discontinuation treatment hepatic glucose output: baseline, after 8 weeks treatment Insulin secretion from oral glucose tolerance baseline, after 8 weeks treatment Body composition baseline & after 8 weeks treatment
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Chula Vista, California, United States